AL
Astellas Pharma Inc.
ALPMY · OTC
$15.43 +1.45% (+$0.22)
1M +2.20%
Market Cap ¥4.36T
P/E Ratio 11.34x
Div. Yield 2.84%
ROE 21.43%
Bulios Fair Price
$11.76
23.8% downside
Current Price
$15.43
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ALPMY is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Strong
8/9Valuation
92 /100
Cheap P/E 11.34x
PEG 0.03x
EV/EBITDA 8.84x
Growth
91 /100
Growing EPS growth 47.21%
Book val. growth 6.84%
Rev. growth 14.31%
Profitability
95 /100
Strong Gross margin 73.34%
FCF margin 22.81%
Net margin 15.93%
Quality
84 /100
Excellent ROIC 15.34%
Asset turnover 0.66x
ROE 21.43%
Debt
91 /100
Low Debt/Equity 0.30x
Net debt/EBITDA 0.64x
Current ratio 1.20x
Stability
45 /100
Moderate Beta 0.09x
Profitable years 6
Rev. volatility 7.70%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ALPMY
Online
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Naoki Okamura
Employees
14,099
Headquarters
Tokyo
Upcoming events
29 SEP
Ex-Dividend
Ex-dividend date
29 OCT
Earnings
Upcoming earnings report
01 DEC
Dividend Payment
Payment date